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mutation for congenital red cell aplasia 
or “DBA” in the current study provides 
important information for genetic coun-
seling of affected families. Clearly, how we 
name diseases is less important than how 
we understand them. As diagnostic DNA 
sequencing becomes increasingly conve-
nient and less expensive, it is more impor-
tant than ever for practicing physicians to 
be aware of the clinical consequences of 
individual gene mutations, the limitations 
of current knowledge, and the fast-moving 
new insights that come our way with the 
advancing technologies of gene discovery.
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WNT signaling plays a central role in the regulation of cellular growth and 
differentiation. In this issue of the JCI, Mori et al. link WNT signaling to 
the oxidative capacity of adipocytes during obesity. They show that secreted 
frizzled-related protein 5 is an extracellular matrix–residing protein that is 
highly induced during obesity and inhibits oxidative phosphorylation in a 
tissue-autonomous manner, possibly by sequestering WNT3a. These results 
implicate local WNT signaling as an attractive target for combating obesity. 
WNTs are secreted proteins that play 
important roles in the regulation of 
many different cellular functions, includ-
ing growth and development. WNTs 
signal via frizzled receptors to activate 
intracellular signaling pathways that lead 
to the stabilization of β-catenin (the so-
called canonical pathway), or they stimu-
late various β-catenin–independent sig-
nals, like Ca2+ influx or JNK activation 
(the noncanonical pathway) (1). Secreted 
frizzled-related proteins (SFRPs) contain-
ing cysteine-rich domains related to those 
of frizzled receptors negatively regulate 
WNT signaling by neutralizing WNTs 
extracellularly (2).
WNT signaling has previously been 
reported to play an important role in 
adipocyte differentiation. The activation 
of β-catenin by WNTs, including WNT6, 
WNT10a, and WNT10b, blocks adipo-
cyte differentiation (3, 4). In contrast, 
the effects of the putative noncanonical 
ligands WNT4 and WNT5a on adipo-
cyte differentiation remain the subject 
of controversy. It has been shown that 
knockdown of WNT4 or WNT5a dimin-
ishes adipocyte differentiation of 3T3-L1 
preadipocytes (5); however, suppressive 
actions of WNT5a treatment have also 
been reported (6).
In this issue of the JCI, Mori, MacDou-
gald, and colleagues report an unexpected 
role of SFRP5 on the oxidative capacity 
of adipocytes in vivo and ex vivo (7). The 
authors confirmed previous findings that 
Sfrp5 mRNA expression is restricted to adi-
pocytes within white adipose tissue (8, 9) 
and showed that Sfrp5 expression was 
induced during late stages of adipocyte dif-
ferentiation. Furthermore, they found that 
Sfrp5 mRNA expression was upregulated 
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(8). Notably, however, suppression of 
SFRP5 expression was observed after 
24 weeks of HFD (8).
Mori et al. showed that Sfrp5 expression 
was induced during adipocyte differentia-
tion (7). In addition, Sfrp5 transcript levels 
in adipose tissue were shown to correlate 
with adipocyte size (7). Consistent with 
this, Sfrp5 expression has been previously 
shown to be induced by refeeding (11).
It is unclear what transcription factors 
account for the induction during differen-
tiation, and chromatin occupancy analyses 
of adipogenic transcription factors have 
not demonstrated binding close to the 
Sfrp5 locus (12, 13). Similarly, the mecha-
nisms inducing expression of the gene dur-
ing obesity and in response to refeeding 
are unknown. It is possible that insulin-
activated factors such as sterol-regulatory 
element binding proteins play a role; how-
ever, proinflammatory signals, secondary 
to the increase in adipocyte size, could also 
be involved during obesity.
Function of SFRP5 in obesity
The results of the present study differ from 
those of the Walsh group in the reported 
effects of genetic ablation of Sfrp5, despite 
a similar genetic background and a com-
Intriguingly, Mori et al. found that the 
adipocytes of obese Sfrp5Q27stop mice had a 
higher oxidative capacity, due to increased 
number as well as increased oxidative 
capacity of mitochondria (7). Importantly, 
this effect must be cell autonomous, since 
adipocytes differentiated in vitro from 
mesenchymal precursors of Sfrp5Q27stop mice 
maintained their oxidative phenotype with 
respect to gene expression and oxygen con-
sumption. Thus, the loss of SFRP5 leads 
to an increase in mitochondrial oxida-
tive capacity in adipocytes, which in turn 
diminishes the accumulation of lipids 
while on HFD (Figure 1).
Sfrp5 expression in obesity
High expression levels of Sfrp5 have pre-
viously been reported as the best a priori 
predictor for a large increase in body 
weight in genetically identical mice (10). 
In line with this, the present study con-
vincingly demonstrated that in many 
models of obesity, including db/db, ob/ob, 
ovariectomized, and HFD-fed mice, 
increased Sfrp5 transcript levels in adi-
pose tissues correlated with adipocyte 
size (7). Similar upregulation of Sfrp5 
protein was documented after 12 weeks 
of HFD by Ouchi, Walsh, and colleagues 
in several mouse models of obesity, with a 
strong correlation between adipocyte size 
and Sfrp5 transcript levels.
SFRP5 blocks the fat furnace
To further investigate the role of SFRP5 in 
adipose biology, the authors used a mouse 
model with an N-ethyl-N-nitrosourea–gen-
erated point mutation in the Sfrp5 locus 
that causes a premature stop codon in the 
first exon (Sfrp5Q27stop mice). These SFRP5-
deficient mice were indistinguishable from 
their WT littermates, and mesenchymal 
stem cells isolated from Sfrp5Q27stop and WT 
mice displayed similar adipogenic differen-
tiation (7). However, when challenged with 
a high-fat diet (HFD), most Sfrp5Q27stop mice 
gained less weight and were more insulin 
sensitive than WT littermates. The resis-
tance to obesity was based on decreased 
appearance of large hypertrophic adipo-
cytes in response to the HFD. This effect 
is at least primarily tissue autonomous, 
since it was recapitulated in adipose tis-
sue transplants independent of the genetic 
background of the host. In support of pri-
marily paracrine/autocrine effects in the 
adipose tissue, SFRP5 was only detected in 
the extracellular matrix, not in the super-
natant, of adipocyte cultures.
Figure 1
SFRP5 is an adipocyte-derived, matrix-resid-
ing protein that sequesters WNTs to reduce 
WNT signaling. Endogenous WNTs stimu-
late the oxidative capacity of adipocytes by 
increasing mitochondrial number and activity. 
During obesity, SFRP5 levels rise, thereby 
suppressing the oxidative metabolism of adi-
pocytes, which subsequently leads to adipo-
cyte hypertrophy. In the absence of SFRP5 
(Sfrp5Q27stop), adipocytes keep their oxida-
tive potential, which leads to an overall shift 
to smaller adipocytes and thus limits weight 
gain. FZ-R, frizzled receptor.
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For example, it has not been shown that 
elevation of WNT3a or WNT5a levels in 
the adipose tissue causes a phenotype simi-
lar to that of SFRP5 loss. It is also possible 
that the action of SFRP5 on adipocytes is 
independent of WNT ligands, as has been 
reported for other SFRPs (22).
Lingering questions
In addition to resolving the conflicting 
data obtained from different Sfrp5-defi-
cient mouse models, a future challenge will 
be to obtain insight into the regulation of 
Sfrp5 expression. It will be particularly 
interesting to uncover the mechanisms 
underlying the increased expression in 
response to obesity and refeeding, condi-
tions that are both associated with high 
insulin levels. Furthermore, it will be 
important to determine which WNT sig-
naling pathways are affected by SFRP5 
deficiency in adipose tissue and to uncov-
er the mechanisms by which SFRP5 and 
WNT signaling modulates nuclear and 
mitochondrial gene expression involved in 
oxidative metabolism.
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rather than their maximal capacity, which 
suggests that WNT3a administration leads 
to induction of slightly different signals 
than does SFRP5 deficiency. In contrast, 
the noncanonical WNT5a was reported to 
account for the effects seen by the Walsh 
group (8). Both WNTs have been shown to 
affect mesenchymal stem cell fate by sup-
pressing adipocyte differentiation. WNT3a 
has been reported to induce COUP-TFII, 
which represses Pparg expression (16), 
whereas WNT5a signaling directs corepres-
sor complexes to PPARγ target sites, there-
by blunting PPARγ transactivation (6). It is 
unclear how this repression of PPARγ activ-
ity would promote obesity in the study by 
the Walsh group (8).
Walsh and colleagues reported that 
SFRP5 counteracts WNT5a-mediated non-
canonical activation of JNK, the activity of 
which is increased by obesity. Consistent 
with this, Sfrp5–/– mice lose their phenotype 
on a Jnk1–/– background (8). However, the 
interpretation is complicated, since HFD-
fed Jnk1–/– mice are resistant to develop-
ing obesity (17), meaning that these mice 
would mimic the lean situation, in which 
ablation of SFRP5 does not affect the 
metabolic phenotype. To strengthen the 
argument for a SFRP5-JNK axis, it would 
be important to determine the cell types 
involved, as JNK activity in different cell 
types has been shown to contribute to obe-
sity and insulin resistance (17). Mori et al. 
demonstrated that SFRP5 loss of function 
did not alter JNK activity in obese mice, 
which indicates that SFRP5 is not a major 
regulator of JNK. Conversely, the authors 
showed that WNT3a signaling could 
mimic the effects of loss of SFRP5 (7). Nei-
ther the Walsh group nor the MacDou-
gald group has yet demonstrated direct 
binding of SFRP5 to WNT3a or WNT5a. 
However, SFRP5 was previously shown 
to bind WNT5a using overexpression of 
tagged proteins (18), and SFRP5 is likely 
to bind WNT3a based on in silico analy-
ses using a human protein-protein inter-
action prediction database, PIP (19, 20). 
It has also been shown that WNT3a and 
WNT5a bind and trigger phosphorylation 
events at different subsets of coreceptors, 
LRP5/6 and ROR1/2, respectively (21). 
Thus, understanding coreceptor avail-
ability and activation would provide some 
insight into the putative WNT signaling 
pathways affected by SFRP5.
In summary, the link between global 
Sfrp5 deletion and the action of the puta-
tive WNT ligands on adipose tissue is weak. 
parable dietary regime. In contrast to the 
antiobesity phenotype of the Sfrp5Q27stop 
mice, the Sfrp5–/– mice used by the Walsh 
group displayed an increase in adipos-
ity, adipocyte size, inflammatory response, 
and insulin resistance after exposure to 
HFD (8). Of note, this metabolic pheno-
type of obese Sfrp5–/– mice was assessed 
after 12 weeks of HFD, at which time Sfrp5 
expression was elevated in WT littermate 
controls. The reason for the difference 
between the phenotypes is unknown, since 
neither of the two targeting strategies is 
predicted to have off-target effects on other 
genes. The Sfrp5Q27stop mice were generated 
by chemical mutagenesis (14) and back-
crossed to C57BL/6 for approximately 20 
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signaling. However, systemic administra-
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tissues, possibly by indirect mechanisms 
via other tissues. Mori et al. suggest that 
SFRP5 decreases mitochondrial oxidative 
capacity in adipocytes and that this defect 
is amplified during obesity as a result of 
increased SFRP5 levels (7).
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Oxidative stress and intracellular infections:  
more iron to the fire
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The immune system’s battle against pathogens includes the “respiratory 
burst,” a rapid release of ROS from leukocytes, thought to play a role in 
destroying the invading species. In this issue of the JCI, Paiva et al. demon-
strate that oxidative stress actually enhances infection with the protozoan 
Trypanosoma cruzi, by a mechanism that may involve facilitating parasite 
access to iron. Their findings suggest a novel direction for the development 
of drugs against intracellular parasites.
The immune system of higher vertebrates 
is capable of rapidly recognizing patho-
gens, mounting an immediate innate 
response. The innate response is followed 
by adaptive immunity, the slower-develop-
ing process that is responsible for prevent-
ing reinfection by the same organism. An 
important component of the rapid innate 
immune response is production of ROS, 
highly reactive and toxic molecules pro-
duced by phagocytes and other cell types. 
ROS have been traditionally viewed as a 
“necessary evil” in the battle against patho-
gens, and their production is coupled to 
antioxidant responses important for miti-
gating oxidative damage in cells and tis-
sues. However, this is clearly not the whole 
story. In this issue of the JCI, Paiva et al. (1) 
demonstrate that antioxidant responses 
actually suppress infections with Trypano-
soma cruzi, a protozoan parasite that seems 
to thrive in an oxidative environment. 
Earlier studies with viruses and bacterial 
pathogens suggested a similar scenario, 
but those observations were mostly attrib-
uted to a role of antioxidant pathways in 
innate immunity. Challenges to estab-
lished dogma are usually slow to emerge, 
but this detailed T. cruzi study raises the 
intriguing possibility that the deleterious 
effects of antioxidants on intracellular 
pathogens may occur by a mechanism fun-
damentally different from classical innate 
or adaptive immune responses.
The role of oxidative stress
This insight came from experiments 
wherein mice and mouse-derived mac-
rophages were exposed to CoPP, an acti-
vator of the transcription factor NRF2 
that orchestrates antioxidant responses. 
NRF2 drives expression of heme oxygen-
ase–1 (HO-1), an enzyme that shifts the 
cellular redox balance by degrading pro-
oxidant heme (2). Surprisingly, activa-
tion of NRF2 and increased expression of 
HO-1 markedly reduced parasite burden 
in infected animals and in isolated macro-
phages. The process was independent of T 
lymphocyte–mediated immunity and did 
not seem to involve apoptotic clearance 
of infected cells or effectors known to be 
active against T. cruzi, such as NO, TNF, or 
type I IFN (1). Remarkably, NRF2 activa-
tion was still able to reduce the very high 
T. cruzi load that is observed in iNOS-
deficient mice. NRF2 activation had the 
expected effect of inhibiting ROS gen-
eration in infected macrophages, but this 
did not affect the number of intracellular 
parasites found shortly after infection (1). 
This observation is consistent with the 
presence in T. cruzi and other trypanoso-
matid parasites of a unique and highly 
effective antioxidant machinery, the try-
panothione-thiol system (3).
The unexpected role of high oxidative 
stress in promoting T. cruzi infection may 
have important implications for the pathol-
ogy of Chagas disease, the chronic debilitat-
ing illness that affects millions of people 
infected by this parasite in Latin America. 
Although infective trypomastigote stages 
can invade practically every nucleated cell 
type, in vivo the parasites are frequently 
found replicating in skeletal and cardiac 
muscle (4). The most serious manifestation 
of chronic Chagas disease, cardiomyopa-
thy, is responsible for significant mortality 
in infected patients and has been directly 
attributed to the persistence of T. cruzi 
within cardiomyocytes (5, 6). Interestingly, 
there is evidence that marked and sustained 
oxidative stress is established in cardio-
myocytes following T. cruzi infection, due 
to parasite-induced disturbances in mito-
chondrial membrane potential and electron 
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